Adam Olszewski
Has grant
Associate Professor of Medicine
United StatesResearch Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Adam Olszewski is an Associate Professor of Medicine at Rhode Island Hospital. His research interests focus on lymphoma treatment and outcomes, particularly in the context of immunotherapy and hematopoietic neoplasms. Recent publications include studies on the efficacy of agents like loncastuximab tesirine and mosunetuzumab in various lymphoma types, addressing both treatment strategies and healthcare spending in oncology.
Recent Grants
Grant: Open
Mosunetuzumab with lenalidomide augmentation as first-line therapy for patients with follicular and marginal zone lymphoma
Open Date: 2022-03-01
Close Date: 2027-02-01
Grant: Close
Clonal hematopoiesis in recipients of myelotoxic therapy for solid tumors
Open Date: 2017-09-01
Close Date: 2018-08-01
Grant: Close
Access to Oral Chemotherapy and Survival Outcomes in Multiple Myeloma
Open Date: 2016-03-01
Close Date: 2019-02-01
Grant: Close
The impact of novel therapies on clinical outcomes and resource utilization in older Americans with Waldenström’s macroglobulinemia.
Open Date: 2015-07-01
Close Date: 2017-06-01
Grant: Close
Skeletal-related events in Medicare beneficiaries with chronic lymphocytic leukemia
Open Date: 2015-06-01
Close Date: 2016-06-01
Articles (16)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Summary Although progression‐free survival (PFS) is a commonly used surrogate end‐point for clinical trials of follicular lymphoma (FL), no analyses have evaluated the strength of surrogacy for PFS with overall survival (OS). A systematic review was performed and 20 studies (total participants, 10 724) met final inclusion criteria. PFS was weakly associated with OS (correlation coefficient; 0.383, p < 0.001). The coefficient of determination was 0.15 (95% CI: 0.002–0.35) suggesting 15% of OS variance could be explained by changes in PFS. This challenges the role for PFS as a surrogate end‐point for clinical trials and drug approvals.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (18)
Umar Farooq
Assistant Professor
University of Iowa Healthcare
Benedito A. Carneiro
-
sairah ahmed
associate professor
The University of Texas MD Anderson Cancer Center
Lihua Budde
Associate Professor
City Of Hope National Medical Center
Andrew Hsu
Assistant Professor of Medicine (Teaching Scholar)
Brown University Warren Alpert Medical School
Tae Min Kim
Seoul National University Hospital
Malathi Kandarpa
University of Michigan
Justin S. Brandt
-
Orestis Panagiotou
Brown University
Ulrich Jaeger
Medical University of Vienna
Lauren Shea
Assistant Professor
The University of Alabama
Christopher Friese
Professor
University of Michigan School of Nursing
Amitkumar Mehta
Assistant professor
The University of Alabama
Tycel Phillips
University of Michigan Medical School
elyce cardonick
Professor
Cooper Medical School of Rowan University
Catherine Diefenbach
Assistant Professor of Medicine
NYU School of Medicine
Ari Pelcovits
-
Peter Barth
Assistant Professor
Brown University Warren Alpert Medical School
ApplyKite TwinLearns as you applyMake your next move.
Prepare your application
Review drafts before you send them.